Advertisement

Topics

Summit signs deal with Eurofarma for Latin American rights to Ridinilazole

19:00 EST 21 Dec 2017 | Pharmaceutical Business Review

Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.

Original Article: Summit signs deal with Eurofarma for Latin American rights to Ridinilazole

NEXT ARTICLE

More From BioPortfolio on "Summit signs deal with Eurofarma for Latin American rights to Ridinilazole"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Clostridium difficile (CDI)
A clostridium difficile infection (CDI) is a type of bacterial infection that can affect the digestive system. It most commonly affects people who are staying in hospital.  The symptoms of CDI can range from mild to severe and include: diarrhoe...